technology has grown from US$5917 million in 1996 to $43,986 million in 2007 [101] , and stem cell research, tissue engineering and gene therapy are key areas receiving priority funding.
In order to better understand China's role in the field of RM, we designed a case study of the RM scene in China. Here, we analyze how China has been able to build capacity in this field and identify its main strengths and challenges. To our knowledge, this is the first such ana lysis relying on original empirical data collection with Chinese experts. This paper will be of interest to the international biomedical research community as it provides a thorough account of the RM scene in China. It will further be of value to policy makers both from within and outside China who are stimulating development of the RM field, as well as all those interested in China's progress in biotechnology and/or health research.
Methods
Our analysis of mainland China's RM R&D is based on qualitative case study methodology, using face-to-face interviews with experts in RM and related fields in China from a wide spectrum of firms and organizations (Table 1) , our own observations in China and a detailed analysis of existing literature. To increase rigor, we triangulated these results with the analyses of Aim: While China has become a significant contributor and prolific publisher in regenerative medicine, its role in the field is not well understood. We analyze how capacity in regenerative medicine was built in China to identify some of its main strengths and challenges. Materials & methods: This case study of regenerative medicine in China is primarily based on interviews with experts in China, including researchers, policy makers, clinicians, representatives of firms and regulators. Results: Our ana lysis shows that diverse groups are active in this field in China. Leading research groups are contributing extensively to international peer-reviewed journals. Strong governmental support and recruitment of highly trained Chinese scientists from abroad has made it possible for China to rapidly build up capacity in regenerative medicine. However, some hospitals in China are offering stem cell therapies with limited scientific evidence supporting their efficacy/safety, and international skepticism of medical research in China presents a challenge to the development of the field. Conclusion: China has been able to catapult itself into the forefront of regenerative medicine but needs to address current regulatory challenges in order to secure its position in this emerging field.
KEYWORDS: China n innovation n regenerative medicine n stem cell therapy ReseaRch aRticle McMahon, Thorsteinsdóttir, Singer & Daar relevant policy documents, government reports and academic publications. n Interviews Through an extensive primary and gray literature review, we identified the main research institutions, universities, hospitals, firms, funding organization, regulatory organizations and policy makers active in this field. We also included supply institutions in RM in our study, including cord blood bank, infertility clinic and animal model experts. As in any country, the quality of RM research in China is of varying quality. The focus of this case study is on the main actors in this field, as we feel they provide the largest contributions to RM development. Our key informants therefore reflect the work of the top researchers in RM and the main firms and hospitals offering stem cell therapies.
Face-to-face interviews were conducted with 47 consenting key informants from a broad spectrum of the institutions listed above using both purposeful and snowball sampling methods. Key informants were all Chinese nationals and were experts in their fields. Interviews of approximately 1-2 h in length were conducted over two field trips to China and were conducted in the language of choice of the interviewee. Interviews were semi-structured, allowing for follow-up questioning and questions specific to the expertise of the interviewee. Interview questions explored current RM research activity in China, funding, regulation and relevant policy initiatives. In addition, questions examined the current strengths and barriers to RM R&D, as well as the future potential of the field, and tried to explore the wider socio-political context of RM R&D in the country.
Interviews were digitally audiotaped and transcribed, and the resulting data were qualitatively analyzed using thematic content analysis. Several rounds of coding were used to identify salient themes and organize themes into conceptual categories. We validated the analysis by carrying out member checks, which entails seeking verification of the findings with participants from the interviews. The research was approved by the Ethics Review Office of the University of Toronto Research Services and informed consent was obtained from each interviewee. n Publication analysis Our scientometric data was generated using keyword searches in the Institute for Scientific Information (ISI) Web of Science expanded citation index. 'Stem cells' or 'stem cell' was used as a topic search term and results were segmented by author's country as listed by the index. Note that China includes mainland China and Hong Kong, and that the UK was composed of publications for England, Scotland, Wales and Northern Ireland. We did not use country names as an address search term to reduce false-cases in which a country name was part of the address other than as the country (e.g., as part of the institute name). All papers generated for each country were then segmented across publication years. The ISI Web of Science citation index is sometimes updated for previous years, which may occasionally generate a small [2] [3] [4] . Although research stagnated for over a decade during and immediately following the Chinese Cultural Revolution in the 1970s, it has in the last decade been gaining momentum. Researchers from Xinhua hospital (Shanghai) were the first in the world to successfully reprogram somatic cells to an embryonic state using nonhuman gametes, which they did by transferring human skin cell nuclei to rabbit oocytes [5] . China has also created at least 25 human embryonic stem cell (hESC) lines to date, including four human embryonic partheno genetic stem cell lines, a type of stem cell line that to our knowledge only two other groups worldwide had created. These numbers are based on our ana lysis of articles published in international peer-reviewed journals. The creation of some stem cell lines may not be published or may only be published in Chinese journals, and some estimate that China has over 70 cell lines [6] . In comparison, Guhr et al. estimated that China, the USA and the UK had developed 21, 38 and four hESC lines, respectively, in 2006 [7] .
Our analysis shows that China's gene therapy research and development have also led to noteworthy gene therapy products. Sibiono in 
Research & development groups
Our interviewees in China identified several institutions that appear to be heavily engaged in basic research in RM. The Institute of Zoology in Beijing is known for their work on animal cloning by somatic cell nuclear transfer, as well as for studies on reprogramming and early embryonic development in cloned animals. In Shanghai, the Center of Excellence in Tissue Engineering does basic research on mesenchymal stem cells and, according to our analysis, is well known as the leading tissue engineering center in China. Researchers at the Peking University Stem Cell Center (Beijing) focus on the gene regulation and differentiation of stem cells, particularly on neural stem cell proliferation. There is also a network of four human stem cell banks being developed in China, with the aim to be a repository of high-quality human stem cell lines for www.futuremedicine.com distribution to researchers in China and abroad. These centers will emphasize the development of embryonic stem cell lines, and are located in Beijing, Shanghai, Guangzhou and within the Chinese Academy of Science. Other types of institutions are also important to this field: fertility clinics serve as a source of discarded embryo nic stem cells for some research in China, and cord blood banks may serve as a source of stem cells for clinical applications. Our ana lysis shows that China has also actively pursued applications of research. Huashan Hospital in Shanghai cultivated human brain tissue in 2002 after taking a sample from the end of a chopstick implanted in a patient's frontal lobe following a disagreement at a restaurant. Neural stem cells were cultured from trauma patients and were reinjected into their brains in the first known controlled clinical trial of adult stem cell therapy for traumatic brain injury [102] . ChinaSCINet also conducts clinical trials on stem cell therapy. Established in 2004, this group is composed of 27 hospitals and spinal cord injury centers across mainland China, Taiwan and Hong Kong. According to the group's website, they are ready to commence Phase II clinical trials to test the efficacy and safety of using HLA-matched cord blood stem cells and oral lithium to treat spinal cord injury in about 40 patients [103] . Researchers in China have begun stem cell clinical trials for several indications, including myocardial infarction, limb ischemia, graft-versus-host disease, liver disease and neural diseases [8] . The Shanghai Tissue Engineering Centre has created several tissue types including blood vessel, tendon, bone, cartilage, skin, cornea and muscle fiber. Its director, who created the famed mouse with cartilage in the shape of a human ear on its back is now in charge of human trials on cranial bone reconstruction using bone marrow stromal cells.
Our ana lysis reveals that many research programs in China are orientated towards treatment of particular diseases. The Xuan Wu Hospital Cell Therapy Center in Beijing is studying the use of fetal neural stem cells and embryonic stem cells for treatment of Type 1 diabetes and has done preclinical trials on monkeys using adult progenitor cells for the treatment of Parkinson's disease [9] . The researchers at Beijing Institute of Transfusion Medicine (Beijing) are studying adult stem cells for the treatment of heart disease, liver disease and blood disease. Researchers at Peking University are studying adult stem cells for the treatment of diabetes, as well as developing novel mouse models with humanized blood and liver systems for vaccine testing with funding from the Grand Challenges in Global Health initiative of the Bill and Melinda Gates Foundation. The Chinese Academy of Science and Shanghai Jiao Tong University School of Medicine (Shanghai) are working on translational medicine focusing on the microdegeneration of aging and on the treatment of cataract eye disease using stem cells.
Firms
The interviews indicate that several firms are active in the RM field in China. SinoCells Biotech (Beijing) is, for example, a spin-off from the Stem Cell Research Center at Peking University. It plans to commercialize therapies for degenerative disease, and is developing a treatment for corneal disease using autologous mesenchymal stem cells. Union Stem Cell and Gene Engineering Company Ltd (StemGene) in Tianjin has developed a cord blood bank and stem cell bank, and is also working on bringing stem cell therapies to market. Shanghai Qisheng is producing wound-healing products and scaffolding material to enhance recovery postsurgery. The National Tissue Engineering Centre (Shanghai) is also a public/private company focused on developing the applications of research in tissue engineering. China can trace its roots in stem cell research back to 1963 when Dizhou Tong cloned an Asian carp, producing the world's first cloned fish and only the second animal to be cloned by nuclear transfer [2] . 10 years later, Tong created the first interspecies clone by transplanting DNA from an Asian carp into the egg of a European carp [3] . Since then, Chinese scientists have used this technique to successfully clone other mammalian species including goats, pigs, cattle and mice. Considered difficult to clone due to oocyte physiology, the first cloned rat was produced from collaboration between the Institute of Zoology in Beijing, a French team from l'Institute National de la Recherche Agronomique (INRA) and the French company GenOway [4] .
Cultivating regenerative medicine innovation in China ReseaRch aRticle lung cancer. When comparing the RM scene in China and India we can see that a stronger private sector presence characterizes the development in the field in the former country, as very few RM firms can be found in India [10] .
Stem cell treatment centers
Several companies and hospitals have moved into RM services and already provide stem cell treatments in more than 200 hospitals across China. They have developed extensive distribution networks for the treatment of diseases such as ataxia, Lou Gehrig's disease, traumatic brain and spinal cord injury, diabetes, Parkinson's disease, multiple sclerosis, autism, cerebral palsy, stroke, optic nerve hypoplasia and many others. They not only treat Chinese patients, but are also targeting large numbers of foreign patients engaging in an increasingly popular but controversial stem cell tourism industry. There is no clinical trial evidence nor peer-reviewed research publications supporting these therapies.
Beike Biotechnology Inc. (Shenzhen) is the largest of these therapy centers and specializes in distributing stem cell therapy to 26 hospitals in China and Thailand. They claim to have treated over 5000 patients to date, including more than 900 foreign patients. According to their website, Beike principally offers purifications of cord blood stem cells or bone marrow stem cells provided surgically, by intravenous injection, or by injections into spinal fluid. Beike has recently joined with Tsingua University (Beijing) to develop a State Key Laboratory on stem cell engineering and reprogramming, for which they have received a US$4 million grant from the Shenzhen government [104] .
The Stem Cell Center affiliated with Tiantan Puhua Neuroscience Hospital in Beijing offers two types of treatments. The first claims to activate and proliferate the body's own neural stem cells through oral and intravenous medications and rehabilitation. The second type of treatment involves a lumbar puncture or brain injection of autologous bone marrow stem cells, fetal neural stem cells or 'human retinal pigment epithelium stem cells' to improve symptoms of stroke, cerebral palsy, spinal injury, Parkinson's disease or other neurological diseases [105] . This group also provides stem cell treatments to patients that travel to Beijing from across North America, Europe and Asia.
Stem cell therapies provided at Beijing Xishan Institute for Neuroregeneration and Functional Recovery have generated considerable debate in both the general media and scientific journals.
Doctors here claim to inject human olfactory ensheathing glial cells from aborted fetuses for the treatment of spinal cord injury and a variety of CNS diseases [106] . According to a representative from the group, so far approximately 1500 patients have received this treatment, approximately 1000 of whom are foreign patients. To our knowledge, this is the only Chinese stem cell therapy examined scientifically that has been published in high-impact journals. One case study documented early motor and sensory improvement of a patient with severe spinal cord injury [11] , whereas another paper published in 2006 found no improvement in seven patients with chronic spinal cord injuries [12] . A recent publication reviewed the efficacy of olfactory ensheathing cell therapies for spinal cord injuries internationally and found functional improvement in some spinal cord injury animal models, but stated that efficacy in humans had not yet been established [13] . n Building RM on China's strengths Regulations According to our interviews, researchers believe that China's permissive stem cell research regulations have helped to propel their biomedicine sector forward (box 2) [14] [15] [16] [17] . These regulations allow therapeutic cloning, the use of surplus embryos or discarded fetal cells from abortions as well as embryos created from somatic cell nuclear transfer or parthenogenetic split blastocytes, activities allowed in several countries. What sets China apart from most of the rest of the world is that these regulations do not prohibit the fusion of human genetic material with nonhuman oocytes. Similarly to other countries worldwide, the regulations prohibit reproductive cloning, the use of human embryos past 14 days postfertilization, the fusion of human and nonhuman gametes, or the implantation of research embryos into human or animal uterus. The stem cell regulations require researchers to provide informed consent to all subjects and require each institute to have an ethics review board which must approve all hESC research. Many stem cell experts consider that although permissive, these regulations are similar to those in the UK and feel that the international community misinterprets the Chinese research regulations as weak.
There was a consensus amongst our interviewees that these permissive regulations are supported by Chinese culture and values, and that many of the oppositions to stem cell research prevalent in the Western world are absent in www.futuremedicine.com
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China. They stressed that the Chinese population does not typically perceive an embryo as having personhood, so the creation and use of embryos is not bound by the same ethical issues hotly debated in some other parts of the world. An interviewee told us, for example, "When we draft our guidelines, we always need to think about our culture as well. For Chinese people, we have not so strong religious ideas about the [embryo]… This is not a person, we don't think so…so we accept." Moreover, the general public appears to have high levels of acceptance of new technologies that are perceived to increase quality of life, particularly when no other recourse of treatment exists.
Governmental support
According to our analysis, the government's support of RM is instrumental to its success. Several State Key Laboratories -laboratories sanctioned by the Chinese government to examine topics of particular national interest -are concentrating on RM research. The 863 and 973 programs are the main national research funding programs for science and technology in China. The 863 program was initiated in 1986, and focuses primarily on the applications of research. Also known as the High Technology R&D program, a key objective of 863 is to develop bioengineering technologies 'for improving the quality of life' and it places emphasis on commercialization and international cooperation. Projects seeking funding are evaluated using criteria on innovation, feasibility and commercial potential of the proposal [107] .
The [108] .
These national priorities are determined by the National Five Year Plans, as set out by the State Government. Other funding strategies that support RM research include the National Natural Science Foundation of China that funds basic science, and city Science and Technology Bureaus. A report by the UK Stem Cell Initiative estimated that MOST will spend between US$73.2 million and US$292.9 million on stem cell research between 2006 and 2010 [109] . The Chinese Academy of Science funds an additional US$20 million of stem cell research per year [110] . These figures are much lower than the amount spent on similar research in the West; however, low wages, physical infrastructure overheads and material costs increase the purchasing power of Chinese currency.
Labor force
Another key strength of China's stem cell research program identified by our analysis is its highly educated labor force. China's stem cell field is comprised of experts, almost all of whom have spent some time training overseas. Called 'sea turtles' for this word's similarity in Chinese to the word for 'overseas returnees', the government has come up with a variety of The first official stem cell policy was released on November of 2002 when the Ministry of Health set the boundaries for stem cell research in a single sentence directive, or the 'Four No's': 'Under no situation, under no circumstances, will human reproductive cloning experiments be 1) endorsed, 2) permitted, 3) supported, or 4) accepted' [14] . These regulations re-articulated the Ministry of Public Health's Five-Point Declaration on Cloning, which bans all trials involving human cloning with no exception for therapeutic cloning [15] . Two separate groups in China felt more specific regulations were needed to oversee an increasingly active stem cell field, and developed draft regulations for proposal to the financial and research incentives to attract sea turtles back to China [1] . Recruiting diaspora is part of the 11th Five Year Plan for 2006-2010 and the Ministry of Personnel has indicated that engaging 'internationally published' returnees in the science sector is of primary importance [111] . The MOST also states its aim to 'set a stage for the outstanding overseas Chinese people to return home to serve the mother land' directly in the 973 funding program. Several of our interviewees stated that almost 100% of researchers active in RM in China had trained abroad and many have had significant working experience in leading stem cell research groups internationally. Low labor costs in China allow these researchers to assemble large labs that provide training for numerous students. This plan is helping to create a favorable educational environment of highly skilled supervisors, which may encourage more students to remain in China following their training. According to a stem cell researcher: "There is a younger generation of scientists being almost completely trained here; to become good professors, to become principal investigators. But overall the number is still low."
Focus on therapy
Our interviewees believe that China's success in RM is due in no small part to their strategic focus on research for the treatment of disease and development of therapy. Approximately 78% of China's funding in research and development is reserved for product development, with an additional 16.8% for applied research [101] . They are also well poised to transition research to applications: China has, for example, developed large primate colonies for preclinical testing, and have already begun clinical trials for a number of therapies (Box 3) [18] . China also has an enormous, supportive population that provides the disease base on which to conduct clinical trials. Experts believe this focus on therapy will help make them an international leader in RM: "I trust on the R&D and the clinical application, [that] we will become one of the leaders in this work." n Challenges for regenerative medicine in China Regulatory concerns According to our research, China's RM field clearly has strengths but equally faces significant challenges. For example, the guidelines for embryo nic research in China have generated international criticism. Because they are guidelines only, they have limited authority over researchers and are not legally binding. Adherence to these rules is enforced only for those who receive funding from the government, which includes most researchers, but financially independent researchers or hospitals must simply answer to their own institution's ethical review board. It is feared that without more comprehensive oversight or firmer regulations, these guidelines may be circumvented. Interviewees stated that enforcement of regulations are a key concern: "We do not have the mature process to examine, so we're not really sure if [the regulations] were implemented totally or not…it is difficult to know whether the policy has been carried out completely because we do not have the examination to really verify". Some of the top stem cell researchers in China have stated that despite this, they consider the stem cell guidelines to be adequate and binding [19] . One interviewee stated "Right now the regulation is, I think it's fine. And I fully support the regulation."
Manipulated stem cells and cells that are proliferated for multiple patient use are considered drugs once they have passed the research phase and are being clinically applied. Their application then requires approval from the SFDA. The MOH is responsible for new clinical procedures that fall outside the regulation of the SFDA. Our review of Chinese regulation and our interviews suggest that one-to-one patient transplantation of unmanipulated stem cells extracted from cord blood or bone marrow currently falls outside the jurisdiction of the SFDA and previous to May 2009 was not considered a novel therapy by the MOH because it has already been approved for use in the treatment of other diseases, such as bone marrow transplant for leukemia. Treatment centers were therefore not required to undergo clinical trials under either the SFDA or MOH, even though efficacy has not been established for the diseases they treat. This has made it possible for the treatment centers to move to treatment early on in the development of the field, but has also hurt the credibility of stem cell therapies in China [12, 19] . As of 1 May, 2009, all stem cell therapies have been classified in China as a Category 3 medical technology, indicating they require proof of safety and efficacy by clinical trial. Gene therapy is already a member of this category, which is directly regulated by the MOH. It is as yet unclear if these new regulations can be circumvented or if they apply to companies that provide stem cells and patients to hospitals, such as Beike [20] , but these regulatory changes could effect the availability of stem cell therapies.
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Unproven therapies
There is currently insufficient scientific examination of available stem cell treatments to conclusively decide their efficacy. The conflicting results published from patient cases at the Beijing Xishan Institute for Neuroregeneration and Functional Recovery, for example, show a pressing need for more systematic evaluation of all new stem cell treatments. Clinical trials of these types of therapies, such as the ChinaSCINet trial, may be able to shed light on their therapeutic merit. Critics have not necessarily questioned the potential of stem cell therapies for treating degenerative disease in the future, but rather felt that the liberal regulations of stem cell therapy in China prior to May 2009 had created a loophole in which treatments could avoid rigorous safety and efficacy testing, and that allowed potentially harmful therapies to market [12] . As such, top Chinese researchers have protested that these centers are acting 'against commonly accepted principles of modern scientific research' and called on the government to ensure patient safety and regulate the efficacy of new treatments [19] . This is a matter of international importance, as increasing numbers of foreign patients are traveling to China to seek unproven stem cell therapies not available in their home countries. The International Society for Stem Cell Research (ISSCR) strongly condemns the administration of unproven stem cell therapies in their Guidelines for the Clinical Translation of Stem Cells and has written a handbook to help doctors and patients make informed decisions about available stem cell therapies [21] . Interviewees acknowledged that these nonevidence-based therapies hurt the credibility of researchers interested in following international scientific standards: "It's a very bad, very bad image for Chinese in this field. So I think the government really should have tight regulations regarding clinical applications." It may be in large part due to these national and international pressures that the MOH revised and tightened the regulation of stem cell therapies.
Lagging basic research
China's push for clinical applications is one of its strengths and has allowed China to produce new scientific knowledge quickly in this field, but this comes at a cost to basic research in China. This has been previously suggested by Salter in 2006 [22] and Chinese researchers still believe basic research aimed at overcoming technical challenges such as controlling how stem cells behave and differentiate is lagging in China and may hold back applied research in the long term. One stem cell researcher stated: "In terms of basic research on regenerative medicine I feel we lack, I think we lag behind". Only 5.2% of China's budget for research and development is allocated to basic research, compared with 13-19% in Japan, Korea and the USA [101] . Even the funds allocated for basic research favor 'strategic basic research' designed to encourage application.
International skepticism
Another challenge to RM in China, stressed by our interviewees, is the international skepticism of scientific results coming from Asia. International credibility is not a struggle uniquely for RM, but common to the biotechnology field in China [23] . One interviewee confirmed that China has been struggling with increased incidents of academic fraud and scientific misconduct, including falsification of resumes, plagiarism and fabrication of data. Some of our interviewees believe that international journals are mistrustful of Chinese scientific integrity and seem to be skeptical of highly innovative discoveries in the stem cell field coming from China. For example, journals held up publication of Hui Zhen Sheng's results of her rabbit oocyte and skin cell chimera for over 2 years [24, 102] . Although there have not yet The availability of quality animal models for regenerative medicine product testing is an essential resource for the transfer of medical products and procedures from lab to clinic. China has developed large, high-quality primate facilities for the preclinical testing of regenerative medicine products. The primate facility at Kunming Institute of Zoology (Kunming) houses 1500 rhesus monkeys and an additional few hundred monkeys of other species [18] . A primate company launched in 2003 in Nanning called Wincon TheraCells Biotechnology breeds 2000 cynomolgus macaques each year. Some of these monkeys are developed to mimic human diseases including Alzheimer's and Parkinson's disease, and diabetes for testing cellular therapies. This facility is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, an international nonprofit group that promotes humane treatment of laboratory animals [18] . Quality animal models and preclinical testing facilities are in demand globally and may attract international researchers to China, promoting partnerships and collaborations between research groups. been any major Chinese stem cell scandals, the Korean Hwang Woo-Suk stem cell line forgery has likely done much to taint the reputation of stem cell research in Asia. A further challenge for Chinese stem cell research relates to scandals involving the SFDA. The head of SFDA Zheng Xiaoyu was executed in 2007 on charges of corruption after accepting bribes to approve drugs, which may have compromised international faith in China's regulatory system. International acceptance is very important if China is going to contribute globally to the field of RM. As one interviewee stated: "International recognition means that thing is real, is true."
Conclusion
Our analysis reveals that China has built an active and innovative RM sector. China's design for fostering innovation combines four key elements: strategic government funding, permissive regulations, a focus on application and a highly educated workforce built by attracting scientific diaspora trained at the foremost stem cell research centers in the world. These different strategies have been well aligned, resulting in a rapid capacity-building of the stem cell field in the country. In particular, the attraction of scientific diaspora to China has resulted in a workforce that is both highly educated and closely connected to major global centers in RM research. This is a lesson other developing countries can consider as they commonly have many of their nationals at eminent centers of learning outside their countries.
Some of these key elements are double edged. For example, permissive regulations lend both a comparative advantage to China as well as being a source of international controversy. The focus on application may come at the expense of fundamental research and a better integration between basic and applied research could help move stem cell research forward in China. The translation of new therapies needs a clear regulatory path, and China should be included in international discourse on translational standards. There is also currently a complete disconnect between applied research and those providing therapy. The new need for clinical testing of stem cell therapies may bridge the interests of academics and industry, and facilitate the transition of research from the lab to the clinic, as well as help define the role of stem cell therapy centers that are currently operating. These new regulations may in time help restore international confidence in Chinese stem cell innovations, but it will take time to evaluate their impact.
Regenerative medicine research in China is subject of national pride and the Chinese feel that their discoveries can help move global research toward clinical solutions. In the words of one stem cell expert: "We don't want to just copy other research, we want to do something innovative. The leaders are first class researchers, they impact the field … we want to be first class, to have an impact." If China continues to build on its strengths and overcome its challenges, China's push towards clinical applications makes 'impact' a likely future reality.
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Executive summary
China's publications on stem cells have increased dramatically over the last decade, placing it as the fifth most prolific country publishing international peer-reviewed papers. A number of institutions are active in basic and applied regenerative medicine (RM) research, including academic institutions, hospitals and firms. Clear government financial and political support has propelled RM in China. Research in RM has been strengthened by 'sea turtles' -returnee Chinese scientists trained overseas. China has developed permissive embryonic stem cell regulations for research, although it is unclear if they are sufficiently enforced. A strong focus on translational medicine and application have strengthened RM in China, although lagging basic research may add challenges in the future. Three main centers in China provide stem cell treatments, targeting both a national and international patient base. Insufficient scientific examination of currently offered stem cell therapies may act as a challenge to the development and commercialization of new treatments. International skepticism is an additional challenge to Chinese biomedical researchers. China has clear strengths in RM, but current challenges need to be addressed in order to secure its position as a global contributor to this emerging field.
